Glurenorm (Gliquidone)

Glurenorm is indicated for the treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient. It may be used as monotherapy or in combination with other antidiabetic agents.

• Improves glycemic control in adults with type 2 diabetes.
• Can be combined with metformin or thiazolidinediones when additional glucose lowering is needed.
• May be considered when other sulfonylureas are not suitable.
• Used as part of a comprehensive diabetes management plan including diet and exercise.
• Prescribed when oral therapy is preferred over insulin initiation.

Glurenorm may cause a range of side effects, some of which are more frequently observed while others are rare but serious.

Common

• Mild hypoglycemia, especially if meals are missed.
• Nausea or gastrointestinal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Skin rash or mild itching.

Serious

• Severe hypoglycemia leading to loss of consciousness.
• Allergic reactions such as swelling of the face, lips, or throat.
• Hepatotoxicity presenting as jaundice or elevated liver enzymes.
• Hematologic abnormalities like leukopenia or thrombocytopenia.
• Pancreatitis with abdominal pain and elevated enzymes.

Before starting Glurenorm, certain health considerations should be reviewed to ensure safe use.

• Assess renal and hepatic function, as impairment may affect drug clearance.
• Caution in patients with a history of cardiovascular disease or arrhythmias.
• Monitor blood glucose regularly to detect hypoglycemia early.
• Use with care during pregnancy or breastfeeding; consult a healthcare professional.
• Adjust dosage in elderly patients due to increased sensitivity.
• Avoid abrupt discontinuation to prevent rebound hyperglycemia.

Glurenorm can interact with several medications, influencing its efficacy or safety profile.

Avoid

• Concurrent use with other sulfonylureas or insulin secretagogues, which may increase hypoglycemia risk.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise gliquidone plasma levels.
• High‑dose aspirin or NSAIDs that may potentiate hypoglycemic effects.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, as they may affect glucose metabolism.
• Anticoagulants, because altered glycemic control can influence INR.
• Oral contraceptives, which may modify drug metabolism.
• Alcohol, which can potentiate hypoglycemia, especially with missed meals.